<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04667650</url>
  </required_header>
  <id_info>
    <org_study_id>CE_20161027_22_AGN</org_study_id>
    <nct_id>NCT04667650</nct_id>
  </id_info>
  <brief_title>Ocular Mysathenia Gravis Generalization</brief_title>
  <acronym>MYASTEN</acronym>
  <official_title>Use of Nomogram for Predictions of Ocular Mysathenia Gravis Generalization</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondation Ophtalmologique Adolphe de Rothschild</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondation Ophtalmologique Adolphe de Rothschild</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Secondary ocular myasthenia gravis (OMG) generalization represents a pejorative evolution and&#xD;
      no validated generalization prevention strategy exists. The aim of this observational study&#xD;
      was to determine the percentage of patients with OMG generalization and identify factors&#xD;
      predictive of that pejorative evolution. Data from patients with OMG registered in the&#xD;
      Fondation Hospital A. de Rothschild database between January 1990 and January 2017 were&#xD;
      collected. Among the 183 patients registered in this database, 151 patients with available&#xD;
      informations were analyzed.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2017</start_date>
  <completion_date type="Actual">January 2020</completion_date>
  <primary_completion_date type="Actual">January 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Time to myasthenia gravis generalization</measure>
    <time_frame>1 year</time_frame>
    <description>Kaplan-meier survival estimations, descriptive and multivariate Cox model analyses were computed (age at onset, first year anti-acetylcholine receptor antibody positivity, electromyogram decrement, steroid use).</description>
  </primary_outcome>
  <enrollment type="Actual">151</enrollment>
  <condition>Ocular Myasthenia Gravis</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Use of nomogram for predictions of Ocular Mysathenia Gravis generalization</intervention_name>
    <description>The outcome measure was time to Myasthenia gravis generalization. The explanatory variables were age at onset, sex, first-year anti-acetylcholinereceptor antibody positivity, repetiting nerve stimulation showing electromyogram decrement and steroid use. Kaplan-Meier survival estimations, descriptive and multivariate Cox model analyses were computed. A nomogram combining explanatory vraiables was used to establish a score to predict the probability of OMG generalization.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with OMG diagnosis and its generalization who consulted between January 1990 to&#xD;
        January 2017 at Fondation Hospital Adolphe de Rothschild and registered in the database&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - Patients with OMG diagnosis and its generalization who consulted between January 1990 to&#xD;
        January 2017 at Fondation Hospital Adolphe de Rothschild and registered in the database&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - OMG differential diagnoses&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Antoine GUEGUEN</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 8, 2020</study_first_submitted>
  <study_first_submitted_qc>December 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 16, 2020</study_first_posted>
  <last_update_submitted>December 8, 2020</last_update_submitted>
  <last_update_submitted_qc>December 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fondation Ophtalmologique Adolphe de Rothschild</investigator_affiliation>
    <investigator_full_name>Amélie Yavchitz</investigator_full_name>
    <investigator_title>Dr Amélie Yavchitz</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myasthenia Gravis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

